M&T Bank’s Cytokinetics CYTK Stock Holding History

M&T Bank’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$720K	Sell	10,928 -272	-2%	-$17.3K	﹤0.01%	965
2025 Q4	$712K	Buy	11,200 +5,188	+86%	+$323K	﹤0.01%	982
2025 Q3	$330K	Buy	+6,012	New	+$248K	﹤0.01%	1158

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

M&T Bank's CYTK Position: Q1 2026 in Review

M&T Bank reduced its Cytokinetics (CYTK) stake by 2.4% in Q1 2026, selling an estimated $17.3K and leaving 10,928 shares worth $720K. The position accounts for ﹤0.01% of the portfolio, ranked #965.

M&T Bank first reported a position in CYTK in Q3 2025 and has held it in 3 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

M&T Bank held 10,928 shares of Cytokinetics worth $720K as of Q1 2026.
M&T Bank sold 272 Cytokinetics shares in Q1 2026, an estimated $17.3K.
Cytokinetics made up ﹤0.01% of M&T Bank's portfolio in Q1 2026, its #965 holding.
M&T Bank first reported a position in Cytokinetics in Q3 2025 and has held it in 3 quarters since.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.